Shots:

• Horizon to acquire Viela Bio for $53/ share- representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s on Jan 29- 2020. Additionally- AstraZeneca to divest its 26.7% ownership in Viela Bio in an exchange of ~$760 - $780M
• The transaction expected to close in Q1’21. The acquisition will bolster Horizon’s pipeline and expand its portfolio of rare diseases with the addition of Uplizna- VIB4920- VIB7734- VIB1116
• Previously- Horizon has submitted a prior approval supplement to the US FDA to support increased scale production of Tepezza for TED

 ­ Ref: Businesswire | Image: CFO